120 related articles for article (PubMed ID: 20331577)
1. The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis.
Orr DW; Patel RK; Lea NC; Westbrook RH; O'Grady JG; Heaton ND; Pagliuca A; Mufti GJ; Heneghan MA
Aliment Pharmacol Ther; 2010 Jun; 31(12):1330-6. PubMed ID: 20331577
[TBL] [Abstract][Full Text] [Related]
2. Prevalence of JAK29V617F) mutation in intra-abdominal venous thrombosis.
Deepak A; Punamiya S; Patel N; Parekh S; Mehta S; Shah N
Trop Gastroenterol; 2011; 32(4):279-84. PubMed ID: 22696908
[TBL] [Abstract][Full Text] [Related]
3. Absence of the JAK2 exon 12 mutations in patients with splanchnic venous thrombosis and without overt myeloproliferative neoplasms.
Fiorini A; Chiusolo P; Rossi E; Za T; De Ritis DG; Ciminello A; Leone G; De Stefano V
Am J Hematol; 2009 Feb; 84(2):126-7. PubMed ID: 19105231
[No Abstract] [Full Text] [Related]
4. Prevalence of Janus Kinase 2 mutations in patients with unusual site venous thrombosis.
Basquiera AL; Tabares AH; Soria N; Salguero M; Ryser R; García JJ
Medicina (B Aires); 2011; 71(4):313-6. PubMed ID: 21893442
[TBL] [Abstract][Full Text] [Related]
5. JAK2 mutations across a spectrum of venous thrombosis cases.
Shetty S; Kulkarni B; Pai N; Mukundan P; Kasatkar P; Ghosh K
Am J Clin Pathol; 2010 Jul; 134(1):82-5. PubMed ID: 20551270
[TBL] [Abstract][Full Text] [Related]
6. The JAK2(V617F) tyrosine kinase mutation identifies clinically latent myeloproliferative disorders in patients presenting with hepatic or portal vein thrombosis.
Goulding C; Uttenthal B; Foroni L; Duke V; Traore A; Kottaridis P; Hoffbrand AV; Patch D; McNamara C
Int J Lab Hematol; 2008 Oct; 30(5):415-9. PubMed ID: 19046316
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of the JAK2 V617F mutation in patients with extrahepatic portal vein thrombosis.
De Stefano V; Fiorini A; Rossi E; Za T; Chiusolo P; Sica S; Leone G
Hepatology; 2007 Mar; 45(3):831-2; author reply 832-3. PubMed ID: 17326212
[No Abstract] [Full Text] [Related]
8. JAK2V617F mutation and myeloproliferative disorders in splanchnic vein thrombosis.
Qi X; Hu F; Yang Z; Han G; Fan D
Aliment Pharmacol Ther; 2011 Feb; 33(4):495-6; author reply 496-7. PubMed ID: 21235599
[No Abstract] [Full Text] [Related]
9. Venous thrombosis in oral contraceptive users and the presence of the JAK2 V617F mutation.
Grandone E; Colaizzo D; Tiscia GL; Vergura P; Chinni E; Iannaccone L; Antinolfi I; Guardascione MA; Margaglione M
Thromb Haemost; 2008 Mar; 99(3):640-2. PubMed ID: 18327418
[No Abstract] [Full Text] [Related]
10. Prevalence of the JAK2 V617F mutation associated with splanchnic vein thrombosis. A 10-year retrospective study.
Tondeur S; Boutruche S; Biron-Andréani C; Schved JF
Thromb Haemost; 2009 Apr; 101(4):787-9. PubMed ID: 19350131
[No Abstract] [Full Text] [Related]
11. Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation.
P'ng S; Carnley B; Baker R; Kontorinis N; Cheng W
Clin Gastroenterol Hepatol; 2008 Apr; 6(4):472-5. PubMed ID: 18328792
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis.
Qi X; Yang Z; Bai M; Shi X; Han G; Fan D
Aliment Pharmacol Ther; 2011 May; 33(10):1087-103. PubMed ID: 21395632
[TBL] [Abstract][Full Text] [Related]
13. JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
Allegra A; Alonci A; Penna G; D'Angelo A; Rizzotti P; Granata A; Musolino C
Acta Haematol; 2009; 121(4):218-20. PubMed ID: 19478480
[TBL] [Abstract][Full Text] [Related]
14. JAK2V617F mutation in patients with thrombosis: to screen or not to screen?
Xavier SG; Gadelha T; Rezende SM; Zalcberg IR; Spector N
Int J Lab Hematol; 2011 Apr; 33(2):117-24. PubMed ID: 21118380
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of the JAK2 V617F mutation for latent chronic myeloproliferative disorders in patients with Budd-Chiari syndrome and/or portal vein thrombosis.
Karaköse S; Oruç N; Zengin M; Akarca US; Ersöz G
Turk J Gastroenterol; 2015 Jan; 26(1):42-8. PubMed ID: 25698270
[TBL] [Abstract][Full Text] [Related]
16. JAK2 V617F mutation, mesenteric vein thrombosis, and myeloproliferative disorders.
Owens CD
J Vasc Surg; 2010 Jul; 52(1):205-7. PubMed ID: 20434300
[TBL] [Abstract][Full Text] [Related]
17. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?
Zerjavic K; Zagradisnik B; Stangler Herodez S; Lokar L; Glaser Krasevac M; Kokalj Vokac N
Acta Haematol; 2010; 124(1):49-56. PubMed ID: 20616539
[TBL] [Abstract][Full Text] [Related]
18. [Detection and clinical significance of JAK2 mutation in 412 patients with chronic myeloproliferative neoplasms].
Chao HY; Fan Z; Zhang R; Shen YM; Chen W; Fei HR; Zhu ZL; Feng YF; Chen ZX; Xue YQ
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):510-4. PubMed ID: 19950698
[TBL] [Abstract][Full Text] [Related]
19. JAK2(V617F) positive early stage myeloproliferative disease (essential thrombocythemia) as the cause of portal vein thrombosis in two middle-aged women: therapeutic implications in view of the literature.
Michiels JJ; Commandeur S; Hoogenboom GJ; Wegman JJ; Scholten L; van Rijssel RH; De Raeve H
Ann Hematol; 2007 Nov; 86(11):793-800. PubMed ID: 17687555
[TBL] [Abstract][Full Text] [Related]
20. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis.
Colaizzo D; Amitrano L; Tiscia GL; Scenna G; Grandone E; Guardascione MA; Brancaccio V; Margaglione M
J Thromb Haemost; 2007 Jan; 5(1):55-61. PubMed ID: 17059429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
